Acceleron Pharma Inc (XLRN) Exchange: NASDAQ

Acceleron Pharma Inc (XLRN) is a biopharmaceutical company located in Cambridge, Massachusetts. Acceleron focuses specifically on the research, development, and commercialization of biotherapeutics for serious, unmet medical need. Since its inception in 2003, Acceleron has built a strong pipeline of drug candidates and achieved a number of key milestones. In 2011, Acceleron entered into a collaboration with Celgene Corporation, a biopharmaceuticals company, to pursue research and development of novel therapies related to the regulation of the TGF-β superfamily of proteins. This collaboration resulted in the development of five clinical-stage drug candidates across multiple therapeutic areas. The collaboration has since been expanded twice and Acceleron continues to make advances in the biotherapeutics field. Acceleron has grown significantly since its founding. From a small startup of 25 employees in 2011, it has grown to more than 400 employees across the US, Europe, and China as of 2020. The company currently has two Phase 3 clinical trials in progress, as well as multiple primary care, rare disease, and oncology products in their research pipeline. Acceleron continues to make strides in the biotherapeutics arena and is committed to improving patient care by delivering innovative solutions and solutions to life-threatening diseases.